Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
- Status
- RECRUITING
- Phase
- PHASE2
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
--SuPERIOR Trial--
- Status
- TERMINATED
- Phase
- PHASE2
Tumor Treating Fields for Locally Advanced NSCLC
- Status
- RECRUITING
- Phase
- PHASE1
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)
- Status
- TERMINATED
- Phase
- PHASE1
Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Durvalumab and Oleclumab in Resectable PDAC
- Status
- RECRUITING
- Phase
- PHASE2
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
- Status
- RECRUITING
- Phase
- PHASE1
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
- Status
- RECRUITING
- Phase
- PHASE2
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
- Status
- RECRUITING
- Phase
- PHASE4
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2